CN100383110C - 治疗嗜中性白细胞依赖性炎症疾病的手性芳香酮 - Google Patents

治疗嗜中性白细胞依赖性炎症疾病的手性芳香酮 Download PDF

Info

Publication number
CN100383110C
CN100383110C CNB200380107685XA CN200380107685A CN100383110C CN 100383110 C CN100383110 C CN 100383110C CN B200380107685X A CNB200380107685X A CN B200380107685XA CN 200380107685 A CN200380107685 A CN 200380107685A CN 100383110 C CN100383110 C CN 100383110C
Authority
CN
China
Prior art keywords
phenyl
methyl
isobutylphenyl
oxo
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200380107685XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1732145A (zh
Inventor
M·阿莱格蒂
R·贝尔蒂尼
M·C·切斯塔
C·比萨里
F·科洛塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe SpA
Dompe PhaRMa SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe SpA, Dompe PhaRMa SpA filed Critical Dompe SpA
Publication of CN1732145A publication Critical patent/CN1732145A/zh
Application granted granted Critical
Publication of CN100383110C publication Critical patent/CN100383110C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/562—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/213—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/213—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C49/215—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C07F9/4059—Compounds containing the structure (RY)2P(=X)-(CH2)n-C(=O)-(CH2)m-Ar, (X, Y = O, S, Se; n>=1, m>=0)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
CNB200380107685XA 2002-12-10 2003-12-09 治疗嗜中性白细胞依赖性炎症疾病的手性芳香酮 Expired - Fee Related CN100383110C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02027453 2002-12-10
EP02027453.6 2002-12-10

Publications (2)

Publication Number Publication Date
CN1732145A CN1732145A (zh) 2006-02-08
CN100383110C true CN100383110C (zh) 2008-04-23

Family

ID=32479711

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200380107685XA Expired - Fee Related CN100383110C (zh) 2002-12-10 2003-12-09 治疗嗜中性白细胞依赖性炎症疾病的手性芳香酮

Country Status (16)

Country Link
US (2) US20060247297A1 (enExample)
EP (1) EP1581474B1 (enExample)
JP (1) JP5021169B2 (enExample)
CN (1) CN100383110C (enExample)
AT (1) ATE406343T1 (enExample)
AU (1) AU2003289993B8 (enExample)
CA (1) CA2507765C (enExample)
CY (1) CY1108596T1 (enExample)
DE (1) DE60323264D1 (enExample)
DK (1) DK1581474T3 (enExample)
ES (1) ES2312834T3 (enExample)
NO (1) NO332223B1 (enExample)
PT (1) PT1581474E (enExample)
RU (1) RU2345759C2 (enExample)
SI (1) SI1581474T1 (enExample)
WO (1) WO2004052830A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2421213C1 (ru) * 2010-02-24 2011-06-20 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Применение 2-гидрокси-3-метил-6-(1-метилэтенил)циклогекс-3-енона в качестве анальгезирующего средства
CN109928868A (zh) * 2019-03-22 2019-06-25 河北科技大学 1,3-双(2,5-二甲基苯基)丙-2-酮的合成方法及其应用
CN115894198B (zh) * 2022-11-04 2024-05-17 浙江永太科技股份有限公司 Qulipta的关键中间体1-(2,3,6-三氟苯基)丙烷-2-酮的制备方法
KR102597093B1 (ko) * 2023-06-07 2023-11-03 옙바이오 주식회사 줄기세포 노화 억제 신규 화합물 및 이의 약학적 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058852A2 (en) * 2000-02-11 2001-08-16 Dompé S.p.A. (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils
CN1324344A (zh) * 1998-10-23 2001-11-28 冬姆佩股份公司 N－(2－芳基－丙酰基)－磺胺类化合物及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125956C (enExample) * 1960-07-26
US3591350A (en) * 1968-06-17 1971-07-06 M & T Chemicals Inc Novel plating process
SE385883B (sv) * 1972-04-10 1976-07-26 Ciba Geigy Ag Forfarande for framstellning av nya pyridinkarbonsyraestrar
JPS5842851B2 (ja) 1976-03-05 1983-09-22 三井東圧化学株式会社 ２−（４′−アルキルフエニル）プロピオン酸の製造方法
US4151172A (en) 1977-08-11 1979-04-24 E. R. Squibb & Sons, Inc. Phosphonoacyl prolines and related compounds
JPS5697249A (en) 1979-12-30 1981-08-05 Ota Seiyaku Kk Preparation of 2-arylalkane acid
JP2782359B2 (ja) 1989-06-22 1998-07-30 日本石油化学株式会社 ２―（４―イソブチルフエニル）―２―ブテン
AU644281B2 (en) 1991-04-24 1993-12-02 Sumitomo Pharmaceuticals Company, Limited Novel thiazole derivatives
JPH05286902A (ja) * 1992-04-10 1993-11-02 Sumitomo Pharmaceut Co Ltd α−クロロ−β−ケトエステル誘導体の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324344A (zh) * 1998-10-23 2001-11-28 冬姆佩股份公司 N－(2－芳基－丙酰基)－磺胺类化合物及其药物组合物
WO2001058852A2 (en) * 2000-02-11 2001-08-16 Dompé S.p.A. (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AN ASYMMETRIC SYNTHESIS OF ACYCLIC ANDMACROCYCLIC a-ALKYL KETONES.. A. I. Meyers, et al.J. Am. Chem. Soc.,Vol.103 . 1981 *

Also Published As

Publication number Publication date
US9328057B2 (en) 2016-05-03
ATE406343T1 (de) 2008-09-15
WO2004052830A1 (en) 2004-06-24
AU2003289993B8 (en) 2008-05-08
NO332223B1 (no) 2012-07-30
RU2005121554A (ru) 2006-01-20
JP2006509022A (ja) 2006-03-16
US20090203652A1 (en) 2009-08-13
AU2003289993A1 (en) 2004-06-30
NO20053086L (no) 2005-06-23
PT1581474E (pt) 2008-12-09
HK1085721A1 (zh) 2006-09-01
JP5021169B2 (ja) 2012-09-05
CN1732145A (zh) 2006-02-08
SI1581474T1 (sl) 2009-02-28
CA2507765A1 (en) 2004-06-24
ES2312834T3 (es) 2009-03-01
CA2507765C (en) 2012-03-20
US20060247297A1 (en) 2006-11-02
DE60323264D1 (de) 2008-10-09
RU2345759C2 (ru) 2009-02-10
AU2003289993B2 (en) 2008-04-24
EP1581474B1 (en) 2008-08-27
DK1581474T3 (da) 2008-12-08
EP1581474A1 (en) 2005-10-05
CY1108596T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
CN100368394C (zh) N-(2-芳基-丙酰基)-磺胺类化合物及其药物组合物
AU2001244125B2 (en) Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils
CN101821243A (zh) 一类嘧啶取代苯丙酸衍生物及其作为ppar激动剂的用途
KR20010034586A (ko) 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
JP6595475B2 (ja) Ｓ１ｐ３アンタゴニスト
EP3630759A1 (fr) Composés inhibiteurs des canaux ioniques pour le traitement du cancer
CN100357280C (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
JP6953538B2 (ja) ビアリール化合物、その製造方法及び用途
US9328057B2 (en) Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases
JP2003518129A (ja) タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなるホスホン酸誘導体
HK1085721B (en) Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases
JP5078622B2 (ja) フェニル安息香酸誘導体、その調製方法、この誘導体を含む医薬品組成物、およびその治療的使用
WO2003004484A1 (en) Novel aliphatic compounds, synthesis method and method of using the same
JP4908211B2 (ja) ブテン酸誘導体、その調製方法、それらを含む薬剤組成物、および脂質代謝異常、アテローム性動脈硬化症および糖尿病の治療のための使用
CN101098846A (zh) 羟基酚衍生物、它们的制备方法、包含它们的药物组合物以及它们的治疗用途
CN118619885A (zh) 芳基并咪唑类化合物及其医药用途
JPWO1999011255A1 (ja) ペルオキシソーム増殖薬活性化受容体制御剤
HK1062675B (en) Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils
JPWO2001014350A1 (ja) 置換ベンジルチアゾリジン−２，４−ジオン誘導体
WO2007085202A1 (en) Oxamic acid derivatives,preparation methods and medical uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1085721

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: DOMPE PHA R MA S P A

Free format text: FORMER OWNER: DOMP S.P.A.

Effective date: 20060908

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060908

Address after: Italy Aquila

Applicant after: Dompe Pha R. Ma S. P. A.

Address before: Italy Aquila

Applicant before: Dompe S. P. A.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1085721

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: DOMPE S.P.A.

Free format text: FORMER OWNER: DOMPE PHA R. MA S. P. A.

Effective date: 20111031

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20111031

Address after: Italy Aquila

Patentee after: Dompe S. P. A.

Address before: Aquila, Italy

Patentee before: Dompe Pha R. Ma S. P. A.

ASS Succession or assignment of patent right

Owner name: DOMPE PHARMACEUTICAL S. P. A.

Free format text: FORMER OWNER: DOMPE S.P.A.

Effective date: 20150902

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150902

Address after: Milan Italy

Patentee after: DOMPE SPA

Address before: Italy Aquila

Patentee before: Dompe S. P. A.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080423

Termination date: 20191209

CF01 Termination of patent right due to non-payment of annual fee